Why the New Schedule M Is a Game Changer for Indian Pharma and How the Industry Is Adapting

The Indian pharmaceutical industry stands at a pivotal moment. With the government's notification of the revised Schedule M in January 2024, the sector is undergoing a structural and cultural transformation. The updated regulations, which bring India’s Good Manufacturing Practices (GMP) in line with global standards, are not just compliance mandates, they represent a paradigm shift towards consistent quality, operational excellence, and global competitiveness.

- Nilesh Patel

Schedule M of the Drugs and Cosmetics Rules, 1945, outlines the GMP requirements for manufacturing pharmaceutical products in India. The revised version enhances and broadens these requirements, integrating principles that focus on quality risk management, validated systems, contamination control, and comprehensive documentation. Key components include upgraded infrastructure norms, air handling systems, water quality management, and stricter environmental monitoring. These reforms aim to ensure that every medicine manufactured in India is safe, effective, and of assured quality.

Phased Compliance Deadlines

The regulatory shift is being rolled out in a phased manner to ensure smoother implementation. Large manufacturers are expected to comply within six months from the date of notification, while micro, small, and medium enterprises (MSMEs) have been given a twelve-month window. This phased timeline recognises the capacity differences across enterprises and allows room for technical and financial preparedness.

Why This Move Matters

India is one of the world's largest suppliers of generic medicines, catering to both domestic needs and export markets across more than 200 countries. In recent years, increased global scrutiny and rising quality expectations from importing countries have underlined the need for stronger, harmonised manufacturing practices. The revised Schedule M is thus a timely intervention that will help elevate India’s global standing in pharmaceutical manufacturing.

Strengthening Quality Assurance